Humacyte (HUMA) Accounts Payables (2020 - 2026)
Humacyte (HUMA) posted quarterly Accounts Payables of $5.1 million for Q1 2026, down 8.79% year-over-year from $5.6 million in Q1 2025, and down 5.96% quarter-over-quarter from $5.4 million in Q4 2025.
Humacyte (HUMA) Accounts Payables (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Accounts Payables for 7 consecutive years, with $5.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 8.79% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (down 8.79% YoY), while the FY2025 annual figure was $5.4 million, up 20.36% from the prior year.
- Accounts Payables fell to $5.1 million in Q1 2026 per HUMA's latest filing, from $5.4 million in the prior quarter.
- Across five years, Accounts Payables topped out at $9.6 million in Q3 2025 and bottomed at $1.6 million in Q4 2022.
- Historically, Accounts Payables has averaged $4.6 million across 5 years, with a median of $4.5 million in 2024.
- On a YoY basis, Accounts Payables climbed as much as 60640.0% in 2022 and fell as far as 44.17% in 2022.
- Humacyte's Accounts Payables stood at $1.6 million in 2022, then soared by 306.9% to $6.5 million in 2023, then plunged by 30.82% to $4.5 million in 2024, then gained by 20.36% to $5.4 million in 2025, then declined by 5.96% to $5.1 million in 2026.
- Business Quant data shows HUMA's Accounts Payables at $5.1 million in Q1 2026, $5.4 million in Q4 2025, and $9.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | 4.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.16 Mn |
| Mar 31, 2026 | 5.08 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Sep 30, 2025 | 9.58 Mn |
| Jun 30, 2025 | 6.63 Mn |
| Mar 31, 2025 | 5.57 Mn |
| Dec 31, 2024 | 4.49 Mn |
| Sep 30, 2024 | 6.90 Mn |
| Jun 30, 2024 | 6.01 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 6.49 Mn |
| Sep 30, 2023 | 3.02 Mn |
| Jun 30, 2023 | 2.36 Mn |
| Mar 31, 2023 | 1.95 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 3.26 Mn |
| Jun 30, 2022 | 2.54 Mn |
| Mar 31, 2022 | 3.04 Mn |
| Dec 31, 2021 | 2.09 Mn |
| Sep 30, 2021 | 5.83 Mn |